Injecting Puragen Plus into the nasolabial folds: Preliminary observations of FDA trial | Zendy

Brian M. Kinney | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Injecting Puragen Plus into the nasolabial folds: Preliminary observations of FDA trial

Author(s) -

Brian M. Kinney

Publication year - 2006

Publication title -

aesthetic surgery journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.528

H-Index - 58

eISSN - 1527-330X

pISSN - 1090-820X

DOI - 10.1016/j.asj.2006.10.008

Subject(s) - medicine , tenderness , erythema , nasolabial fold , surgery , clinical trial , patient satisfaction , double blind , cosmetic techniques , alternative medicine , pathology , placebo

Based on participation in ongoing FDA trials, the author presents his initial impressions of Puragen Plus for treatment of the nasolabial folds. Puragen and Puragen Plus (Mentor Corp., Santa Barbara, CA) are double-cross-linked NASHA products. Depending on double cross-linking for duration of effect, instead of a varying particle size, may allow for use of one filler at all levels in the soft tissue. Other features observed by the author in the clinical setting included reduced injection pain, minimal erythema and tenderness, typically 9 to 12 months' duration of effect, and high patient satisfaction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research